10-Q: Rafael Holdings Reports Q2 2025 Results, Impacted by Goodwill Impairment and Cyclo Therapeutics Investment

Sentiment:

Quarterly Report 13 March 2025 10:11 PM

Rafael Holdings' Q2 2025 results reveal a net loss, influenced by a goodwill impairment in the Infusion Technology segment and fluctuations in the fair value of its investment in Cyclo Therapeutics.

Delay expectedThe Series C Convertible Notes are currently in default as they are beyond the maturity date.The installment note payable of $1.7 million is currently in default as it is beyond the maturity date.

Capital raiseThe company has agreed, so long as Cyclo is not in active discussions regarding an acquisition proposal, to fund Cyclo through the earlier of the consummation of the business combination or termination of the Merger Agreement in such amounts as may be necessary for Cyclo to operate its business and pay its debts and obligations as they become due.Following the closing, the Company will fund Cyclos TransportNPC clinical trial to its 48-week interim analysis up to a maximum amount, when added to the Pre-Closing Funding, of $25 million.On February 4, 2025, Rafael entered into an Eighth Amended and Restated Note Purchase Agreement with Cyclo, pursuant to which Cyclo issued and sold a convertible promissory note in the principal amount of $2 million (the Cyclo Convertible Note IX) to Rafael for $2 million in cash.On March 6, 2025, the Company entered into a Ninth Amended and Restated Note Purchase Agreement with Cyclo, pursuant to which Cyclo issued and sold a convertible promissory note in the principal amount of $2.5 million (the Cyclo Convertible Note X) for $2.5 million in cash.

Worse than expectedThe company reported a net loss compared to a net income in the same period last year.The company recorded a loss from operations compared to a loss in the same period last year.The company recorded a significant unrealized loss on the investment in Cyclo Therapeutics.The company recorded a goodwill impairment charge in the Infusion Technology segment.

Summary

Rafael Holdings, Inc. reported its financial results for the quarter ended January 31, 2025.
The company is a holding company with interests in clinical and early-stage pharmaceutical companies, including Cyclo Therapeutics, LipoMedix Pharmaceuticals, Barer Institute, Cornerstone Pharmaceuticals, Rafael Medical Devices, and Day Three Labs.
A planned merger with Cyclo Therapeutics is underway, with the intention to focus on Trappsol Cyclo as the lead clinical program.
The company's primary focus is expanding its investment portfolio through strategic investments in therapeutics addressing unmet medical needs.
The company is evaluating its operating entities to focus resources on core assets, specifically Trappsol Cyclo clinical and development efforts.
The company's remaining revenue-generating real estate asset is a portion of a commercial building in Jerusalem, Israel.
The company has three reportable segments: Healthcare, Infusion Technology, and Real Estate.
A goodwill impairment charge of $3.1 million was recorded in the Infusion Technology segment.
The company held cash and cash equivalents of approximately $48.3 million as of January 31, 2025.
The company expects its cash and cash equivalents to be sufficient to meet its obligations for at least the next 12 months.
The company is funding Cyclo Therapeutics through convertible notes, with $16.589 million outstanding as of January 31, 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture, with positive developments such as FDA clearance for the VECTR System and increased cash reserves, but these are overshadowed by the net loss, goodwill impairment, and unrealized losses on investments. The ongoing merger with Cyclo adds uncertainty, and the company's future success hinges on the outcomes of clinical trials and regulatory approvals.

Positives

Cash and cash equivalents increased significantly to $48.319 million as of January 31, 2025, compared to $2.675 million as of July 31, 2024.
Rafael Medical Devices received FDA clearance for the VECTR System in December 2024.
The company expects its cash and cash equivalents to be sufficient to meet its obligations for at least the next 12 months.

Negatives

Rafael Holdings reported a net loss of $5.327 million for the three months ended January 31, 2025, compared to a net income of $5.904 million for the same period in 2024.
The company recorded a loss from operations of $6.639 million for the three months ended January 31, 2025, compared to a loss of $3.143 million for the same period in 2024.
A significant unrealized loss of $3.751 million was recognized on the investment in Cyclo Therapeutics for the six months ended January 31, 2025.
The Infusion Technology segment recorded a goodwill impairment charge of $3.1 million.

Risks

The company's financial results are subject to fluctuations in the fair value of its investments, particularly in Cyclo Therapeutics.
The company's future success depends on the successful development and commercialization of its pharmaceutical products.
The company faces risks associated with clinical trials, regulatory approvals, and market acceptance of its products.
The company's Infusion Technology segment is facing challenges, as evidenced by the goodwill impairment and reductions in operations.
The planned merger with Cyclo Therapeutics is subject to various conditions and may not be consummated.

Future Outlook

The company intends to focus its efforts on making Trappsol Cyclo its lead clinical program upon closing of the planned Merger with Cyclo, and will fund the TransportNPC Phase 3 clinical trial to its interim analysis in the middle of 2025, at which point the company will make a determination as to whether or not to file an NDA for Trappsol Cyclo.

Management Comments

The Company is currently reviewing Cornerstones current efforts, prospects and available resources to determine the optimal operational direction.
The Company is evaluating the prospects for Day Threes technology and offerings in light of current regulatory and commercial conditions.

Industry Context

The company's focus on clinical-stage pharmaceutical companies and cancer metabolism-based therapeutics aligns with broader industry trends in personalized medicine and targeted therapies. The planned merger with Cyclo Therapeutics reflects a strategic move to consolidate resources and focus on a lead clinical program in a high-need area.

Comparison to Industry Standards

It is difficult to compare Rafael Holdings directly to industry standards due to its unique structure as a holding company with diverse investments.
However, the company's investments in clinical-stage pharmaceutical companies can be compared to similar companies in the biotechnology sector.
For example, Cyclo Therapeutics, with its focus on Niemann-Pick Disease Type C1, can be compared to other rare disease drug developers such as BioMarin Pharmaceutical and Ultragenyx Pharmaceutical.
Cornerstone Pharmaceuticals, with its focus on cancer metabolism, can be compared to companies like Agios Pharmaceuticals and Forma Therapeutics (now part of Novo Nordisk).
The success of these investments will depend on factors such as clinical trial outcomes, regulatory approvals, and market access, which are common challenges in the pharmaceutical industry.

Related Party Transactions

IDT Corporation, a related party through common ownership and some common members of management, has historically maintained a due to/from balance that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT and payroll costs for the Companys personnel that were paid by IDT as the relevant persons were also providing services to IDT.
IDT currently leases approximately 3,600 square feet of office space and parking space in our real estate asset.
The Company leased space to related parties (including IDT Corporation) which represented approximately 38% and 40% of the Companys total revenue for the three months ended January 31, 2025 and 2024, respectively.
On July 31, 2023, eight trusts, each for the benefit of a child of Howard S. Jonas, the Companys Executive Chairman and Chairman of the Board, with independent trustees, transferred an aggregate of 787,163 shares of Class A common stock of the Company to a limited partnership.
During the three and six months ended January 31, 2025, the Company paid Sam Beyda, who serves as Chief Executive Officer and a Director of Day Three and is Howard Jonas son-in-law, a salary o f $36.6 thousand, and a salary of $73.2 thousand plus a bonus of $21.1, respectively.

Stakeholder Impact

Shareholders: The net loss and goodwill impairment may negatively impact shareholder value in the short term, but the potential merger with Cyclo and focus on Trappsol Cyclo could create long-term value.
Employees: Reductions in operations in the Infusion Technology segment may lead to job losses.
Customers: The FDA clearance for the VECTR System could benefit patients seeking minimally invasive surgical options.
Creditors: The company's increased cash reserves improve its ability to meet its obligations.
Partners: The company's strategic direction and focus on core assets may impact its relationships with partners in non-core areas.

Next Steps

The company will continue to work towards consummating the merger with Cyclo Therapeutics.
The company will fund Cyclo's TransportNPC clinical trial to its 48-week interim analysis.
The company will evaluate its operating entities to focus resources on core assets.
The company will continue to develop and commercialize its pharmaceutical products.
The company will monitor the performance of its Infusion Technology segment and take steps to address the challenges it is facing.

Key Dates

Date	Description
2017-01-01	FDA granted Fast Track designation to Trappsol Cyclo for the treatment of NPC1.
2017-09-01	Initial patient enrollment in the U.S. Phase I study commenced for Trappsol Cyclo.
2019-01-01	The Company established Barer, a preclinical cancer metabolism research operation.
2020-05-01	Cyclo announced Top Line data showing Trappsol Cyclo was well tolerated in the Phase 1 study.
2021-05-01	The Company formed Rafael Medical Devices, an orthopedic-focused medical device company.
2022-11-01	The Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer.
2023-04-14	The Companys Board of Directors approved a share repurchase program.
2023-05-02	The Company entered into a Securities Purchase Agreement with Cyclo.
2023-08-01	The Company purchased an additional 4,000,000 shares of common stock of Cyclo.
2023-10-20	The Company exercised the May Warrant to purchase 2,514,970 common shares of Cyclo.
2024-01-02	The acquisition date for Day Three, when Rafael obtained a controlling interest.
2024-03-13	Cornerstone consummated a restructuring of its outstanding debt and equity interests, resulting in Rafael becoming a 67% owner.
2024-08-21	The Company entered into a Merger Agreement with Cyclo.
2024-12-11	Rafael Medical Devices received FDA clearance for the VECTR System.
2024-12-23	Rafael exercised its discretionary conversion option under the Cyclo Convertible Notes, converting $2.5 million in outstanding principal amount of the Cyclo Convertible Note III.
2025-01-31	End of the current reporting period.
2025-03-13	Date of the certifications by the CEO and CFO.

Keywords

Rafael Holdings, Cyclo Therapeutics, Financial Results, Merger, Trappsol Cyclo, LipoMedix, Cornerstone Pharmaceuticals, Goodwill Impairment, Pharmaceuticals, FDA, VECTR System, Investment, Net Loss, Clinical Trials

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.